{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-013078","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2022-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.568251+00:00","generated_at":"2026-06-24T08:38:45.576983+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sutro Biopharma receives $10M milestone from Merck after first patient dosed in Phase 1 collaboration study","bullets":["Merck pays Sutro $10.0 million milestone following first patient dosing in Phase 1 study of a collaboration candidate.","No other financial terms or guidance disclosed; collaboration continues.","Specific investigational candidate not named in the filing.","Milestone payment triggers positive cash inflow for Sutro's development programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-013078","json":"https://secwatch.observer/filing/0000950170-22-013078.json","markdown":"https://secwatch.observer/filing/0000950170-22-013078.md","text":"https://secwatch.observer/filing/0000950170-22-013078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022013078/0000950170-22-013078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022013078/stro-20220726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:38:45.576983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}